Moreover, it has been shown that in a certain group of patients with BRCA1/BRCA2 wild type, they present an immune profile of the tumor showing the expression of PD-1/PDL-1 that would benefit from the treatment of iPARP associated with immunotherapy directed at these two biomarkers. Here, BRCA2 is linked to neoplasm.